Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
41.73
+0.30 (+0.72%)
Streaming Delayed Price
Updated: 11:44 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
26
27
Next >
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
March 30, 2022
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Why Are ImmunoGen Shares Trading Lower Today
March 21, 2022
ImmunoGen Inc (NASDAQ: IMGN)
Via
Benzinga
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From
Genentech
Via
Business Wire
Biotech Funds and ETFs Continue to Lag
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
Drug makers, Scientists Working For Long COVID Treatments: Reuters
March 25, 2022
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Via
Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
March 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Flood Helping Ukraine
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
Up On Bad News
March 22, 2022
Despite the plane crash in China, Boeing's stock is up today.
Via
Talk Markets
World Markets News For Friday
March 18, 2022
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.
Via
Talk Markets
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
Via
Benzinga
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing
March 16, 2022
If approved, this would be the company's second drug to hit the U.S. market.
Via
Investor's Business Daily
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
March 16, 2022
From
Genentech
Via
Business Wire
The OTCQX's Top 10 Experience A Shuffle In February
March 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Hopes For A Peace Accord
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
March 14, 2022
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and...
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
March 09, 2022
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities.
Via
Investor's Business Daily
OTC Markets 2021 Annual Data Review Highlights A Record 60% $ Volume Increase
March 07, 2022
Photo by Sophie Bakes on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The...
Via
Benzinga
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Holiday Over
February 22, 2022
China is busily avoiding taking sides between Ukraine and Russia.
Via
Talk Markets
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
February 14, 2022
Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.